Business
Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical Company
Positions Lifeward as a diversified biomedical innovation company with clear path to profitability Integration of Oramed’s POD™ oral delivery technology expands Lifeward into biotech markets while Oramed funds the platform’s clinical development Provides Lifeward access to up to $47 million of capital HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 13, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform
About this update from Lifeward Ltd.
[{"type":"image","alt":"Lifeward Ltd.","displaySize":"","headline":null,"caption":"Lifeward Ltd.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":214,"url":"https://media.zenfs.com/en/globenewswire.com/650bbdd4116421044d82c00fb4f6ebe6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/wsdrGKJN7fPKThSBzlEhlA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMwMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/650bbdd4116421044d82c00fb4f6ebe6","width":300,"height":214}},"lazy":false},{"type":"text","content":"Positions Lifeward as a diversified biomedical innovation company with clear path to profitability","length":98,"tagName":"p"},{"type":"text","content":"Integration of Oramed’s POD™ oral delivery technology expands Lifeward into biotech markets while Oramed funds the platform’s clinical development","length":146,"tagName":"p"},{"type":"text","content":"Provides Lifeward access to up to $47 million of capital ","length":56,"tagName":"p"},{"type":"text","content":"HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 13, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that its shareholders approved the issuances of ordinary shares of the Company in connection with closing of the Company’s previously announced strategic partnership agreement with Oramed Pharmaceuticals Inc. (Nasdaq: ORMP).","length":501,"tagName":"p"},{"type":"text","content":"“This is a defining moment in Lifeward’s evolution,” said Mark Grant, President and CEO of Lifeward. “With this partnership now moving towards closing, we believe Lifeward is uniquely positioned to combine the strength of our proven medical technology platform with the long-term potential of the POD™ oral delivery technology. We are building a disciplined, diversified biomedical innovation company that we believe can deliver both near-term financial performance and meaningful long-term growth opportunities for shareholders.”","length":530,"tagName":"p"},{"type":"text","content":"Grant continued, “We remain focused on driving profitability across our core neuro-rehabilitation business while selectively investing in complementary technologies that have the potential to reshape major therapeutic markets. This transactio...